Literature DB >> 16782957

Bilateral ocular metastasis from an occult primary melanoma.

D Verhulst, P Demaerel, B Damato, A Leys.   

Abstract

Entities:  

Mesh:

Year:  2006        PMID: 16782957      PMCID: PMC1857158          DOI: 10.1136/bjo.2006.092445

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  8 in total

Review 1.  Intraocular metastases of cutaneous malignant melanoma: a case report and review of the literature.

Authors:  K Ramaesh; J W Marshall; S B Wharton; B Dhillon
Journal:  Eye (Lond)       Date:  1999-04       Impact factor: 3.775

2.  [Metastatic melanoma of unknown primary site].

Authors:  F Laveau; M C Picot; O Dereure; J J Guilhou; B Guillot
Journal:  Ann Dermatol Venereol       Date:  2001-09       Impact factor: 0.777

3.  Survey of 520 eyes with uveal metastases.

Authors:  C L Shields; J A Shields; N E Gross; G P Schwartz; S E Lally
Journal:  Ophthalmology       Date:  1997-08       Impact factor: 12.079

4.  Intraocular metastases from cutaneous malignant melanoma.

Authors:  S de Bustros; J J Augsburger; J A Shields; E P Shakin; C C Pryor
Journal:  Arch Ophthalmol       Date:  1985-07

5.  Bilateral uveal melanoma: a series of four cases.

Authors:  P W Hadden; B E Damato; I C McKay
Journal:  Eye (Lond)       Date:  2003-07       Impact factor: 3.775

6.  Early lesions of bilateral diffuse melanocytic proliferation.

Authors:  A M Leys; H G Dierick; R M Sciot
Journal:  Arch Ophthalmol       Date:  1991-11

7.  The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society.

Authors:  A E Chang; L H Karnell; H R Menck
Journal:  Cancer       Date:  1998-10-15       Impact factor: 6.860

Review 8.  Paraneoplastic syndromes associated with visual loss.

Authors:  Cecilia P W Ling; Carlos Pavesio
Journal:  Curr Opin Ophthalmol       Date:  2003-12       Impact factor: 3.761

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.